- Lilly’s weight loss drug cuts diabetes risk by 94% in three-year trial, company saysNBC News
- Eli Lilly’s weight loss drug slashes the risk of developing diabetes in long-term trialCNBC
- Mounjaro/Zepbound Drastically Cuts Risk Of Type 2 Diabetes, Eli Lilly Report SuggestsForbes
- Eli Lilly’s weight loss drug almost eliminates the risk of diabetes in overweight adultsQuartz
- Lilly Stock Jumps. Mounjaro Looks Unstoppable as Trial Wins Pile Up.Barron’s